Experimental and Clinical Psychopharmacology
July 24, 2025
Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma et al.
Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use disorders. Data are lacking, however, regarding the potential influence of ketamine on other substance use. In this secondary analysis, we aimed to explore the relationship between medical ketamine and other substance use among real-world patients by...
Experimental and Clinical Psychopharmacology
October 1, 2024
Kaitlyn J Partridge, Todd M. Hillhouse
1 citation
Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To...
Experimental and Clinical Psychopharmacology
November 27, 2023
Jakub Greń, Ingmar Gorman, Anastasia Ruban et al.
27 citations
The use of psychedelics for various purposes was common in different civilizations throughout human history and has been explored scientifically for more than a century. Although the applications of psychedelics show promise in the treatment of various psychiatric and neurological indications, as well as in facilitation of well-being and personal growth, several psychedelic-related risks and...
Experimental and Clinical Psychopharmacology
April 1, 2023
Brett Melanson, Michael Wolter, Zion Leatham et al.
This study was designed to explore the clinical belief that "set and setting" play an important role in favorable responses to psychedelic agents such as ketamine (KET). In fact, there is evidence in animals that the antidepressant effect of this drug may involve drug-environment interactions in which a context paired with its effects acquires the ability to influence behavior. Therefore, it...
Experimental and Clinical Psychopharmacology
February 1, 2023
Luke Herchenroeder, Eleanor Williams, Emma Wedell et al.
Prior research suggests brief mindfulness (breath counting) interventions may be effective at attenuating stress-induced alcohol-related cravings. However, it remains unclear whether this reduction in craving is due to increased state mindfulness or mere distraction. To test this, the present study examined whether brief breath counting would attenuate a stress-induced increase in the relative...
Experimental and Clinical Psychopharmacology
September 1, 2022
Julie A E Christensen, David C. Fipps, J Michael Bostwick
4 citations
Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...
Experimental and Clinical Psychopharmacology
November 4, 2021
Tânia Cristina Libânio, R. Eufrásio, Suzy S Niigaki et al.
6 citations
The interest in psychedelic substances as potential treatments for psychiatric disorders is increasing. The β-carboline harmine, an Ayahuasca component, presents hallucinogenic and antidepressant effects. Although Ayuahuasca-and consequently harmine-is usually consumed in rituals, the role of social contexts in the behavioral effects of harmine has not been investigated yet. In this sense,...
Experimental and Clinical Psychopharmacology
June 7, 2021
Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al.
53 citations
Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...
Experimental and Clinical Psychopharmacology
January 10, 2019
Farhana Sakloth, Elizabeth Leggett, Megan J. Moerke et al.
42 citations
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse and depression. The goal of the...
Experimental and Clinical Psychopharmacology
February 1, 2018
Michael Mathews, R. N. Mead, M. Galizio
The glutamate hypothesis proposes that N-Methyl-D-aspartate (NMDA) receptor hypofunction underlies cognitive and perhaps other schizophrenic symptoms. The present study used the odor span task to assess the effects of NMDA antagonists on remembering multiple stimuli in rodents. This task uses an incrementing nonmatching-to-sample procedure in which responses to a new olfactory stimulus are...
Experimental and Clinical Psychopharmacology
February 1, 2008
William E Fantegrossi
30 citations
The chiral nature of the MDMA molecule gives rise to two enantiomers, each of which is biologically active. This review attempts to cover the author's research into the in vivo effects of MDMA and its enantiomers, as well as other relevant publications which pertain to this topic. No particular differences between the capacities of racemic MDMA and its enantiomers to maintain behavior were...
Experimental and Clinical Psychopharmacology
November 1, 2006
Michelle R Lofwall, Roland R. Griffiths, Miriam Z Mintzer
57 citations
Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) antagonist. Given the purported role of the NMDA receptor in long-term potentiation, the primary purpose of the present study was to further understand the dose-related effects of ketamine on memory. The study was also designed to provide information about the relative effects of ketamine on memory versus nonmemory effects and to more...
Experimental and Clinical Psychopharmacology
2005
Catharine Montgomery, John E. Fisk, Russell Newcombe et al.
22 citations
Previous research has demonstrated working memory and executive deficits in recreational users of MDMA (3,4-methylenedioxymethamphetamine; Ecstasy). In turn, both of these constructs have been implicated in syllogistic reasoning performance. Twenty-two MDMA users (mean age = 21.36) and 26 MDMA nonuser controls (mean age = 21.31) were tested on syllogisms of varying difficulty and on measures of...
Experimental and Clinical Psychopharmacology
2000
A. K. Goodwin, L. E. Baker
44 citations
(+/-)-3,4-Methylenedioxymethamphetamine (MDMA) produces subjective effects in humans that are similar to, but distinguishable from, those of psychostimulants. Drug discrimination studies in nonhumans have yielded inconsistent results regarding the similarities between MDMA and the psychomotor stimulant d-amphetamine. This study successfully used a 3-choice operant procedure to establish MDMA...
Experimental and Clinical Psychopharmacology
May 1, 1997
I Moroz, Linda A. Parker, S Siegel
11 citations
The ability of ibogaine, injected 24 hr before amphetamine, to modify the establishment of amphetamine-induced place preference learning was assessed. A single injection of ibogaine blocked the establishment of amphetamine place preference after 1 or 2 conditioning trials, but it was less effective after 4 trials. The reduced effectiveness of ibogaine across multiple conditioning trials appears...